Corgentech to Start Human Eczema Trial
Monday May 9, 2:32 pm ET
Corgentech to Begin Eczema Drug Trials on Humans Following Favorable Preclinical Results
SOUTH SAN FRANCISCO, Calif. (AP) -- Biopharmaceutical company Corgentech Inc. said Monday that it plans to begin two clinical trials by midyear to test its eczema treatment in humans following favorable preclinical results.
ADVERTISEMENT
Corgentech shares rose 14 cents, or 5.9 percent, to $2.50 in afternoon trading on the Nasdaq.
The company said that preclinical testing showed that its drug candidate NF-kappaB Decoy decreased inflammation and swelling in animal models for eczema without posing a significant cancer risk.
In early March, the Food and Drug Administration required two eczema drugs, Protopic and Elidel, to carry black box warnings on their labels citing a potential cancer risk. Fujisawa Healthcare Inc. makes Protopic and Novartis AG's Novartis Pharmaceuticals Corp. makes Elidel.
Corgentech said it plans to enroll 75 U.S. patients in one study and 120 Australian and Swiss patients in the other study.
Eczema is a condition affecting 15 million in the United States and is characterized by itchiness, redness and thickening of the skin from elevated levels of immunoglobulin E, the company said. NF-kB Decoy acts to inhibit the transcription factor NF-kB, which is implicated in inflammatory diseases.
Novartis American depositary shares fell 14 cents to $49.40 on the New York Stock Exchange.
Email Story
Set News Alert
Print Story
Caspermick
"TOUGH TIMES NEVER LAST BUT TOUGH PEOPLE DO."
God Bless America
In Gambling,,,Playing Card Games. Ya Never Know What The Next Hand Will Look Like.
Ten Bagger Potential Stock
AI
